For the year ending 2025-12-31, NVCR had -$62,704K decrease in cash & cash equivalents over the period. -$75,679K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -136,227 |
| Depreciation and amortization | 14,650 |
| Accrued interest | 4,949 |
| Asset write-downs and impairment of field equipment | 4,851 |
| Share-based compensation | 104,832 |
| Foreign currency remeasurement loss (gain) | -1,251 |
| Decrease (increase) in accounts receivables and prepaid expenses | 38,938 |
| Amortization of discount (premium) | -23,262 |
| Decrease (increase) in inventories | 5,668 |
| Decrease (increase) in other long-term assets | -10,847 |
| Increase (decrease) in accounts payables and accrued expenses | 18,958 |
| Increase (decrease) in other long-term liabilities | -5,274 |
| Net cash provided by (used in) operating activities | -49,031 |
| Purchase of property, equipment and field equipment | 26,648 |
| Proceeds from maturity of short-term investments | 1,285,000 |
| Purchase of short-term investments | 821,076 |
| Net cash provided by (used in) investing activities | 437,276 |
| Proceeds from issuance of shares, net | 3,656 |
| Proceeds from senior secured credit facility, net | 99,979 |
| Repayment and redemption of long-term debt | 560,945 |
| Tax payments related to net settlements on equity awards | 146 |
| Exercise of options | 6,113 |
| Net cash provided by (used in) financing activities | -451,343 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 394 |
| Increase (decrease) in cash, cash equivalents and restricted cash | -62,704 |
| Cash, cash equivalents and restricted cash at the beginning of the year | 166,094 |
| Cash, cash equivalents and restricted cash at the end of the year | 103,390 |
NovoCure Ltd (NVCR)
NovoCure Ltd (NVCR)